Key result
Trastuzumab treatment was associated with declines in left atrial reservoir strain at 3 months, especially in those developing cardiac dysfunction (delta -4.7%; 95% CI -8.1% to -1.3%; p=0.007).
Why the study?
The effect of trastuzumab therapy on left atrial function remains largely unknown.
Does trastuzumab therapy reduce left atrial strain parameters in patients with HER2+ breast cancer?
Cohort (n=170)
Does trastuzumab therapy reduce left atrial strain parameters in patients with HER2+ breast cancer?
Mean Difference: -4.7 (95% CI -8.1–-1.3)
p-value: p=0.007
Trastuzumab therapy in breast cancer patients is associated with significant declines in left atrial strain parameters, particularly in those who develop cancer therapeutics-related cardiac dysfunction.
May signal early CTRCD risk with trastuzumab but should not yet change practice; leaves open prospective validation of LA strain monitoring.
Background The effect of trastuzumab therapy on left atrial (LA) function remains largely unknown. Our aim was to assess the changes in LA strain parameters longitudinally in patients treated with trastuzumab. Methods We retrospectively studied 170 patients with stage I‐IV HER2+ breast cancer. All patients had baseline echocardiograms and repeat echocardiograms at 3 months and after 1 year. We measured LA strain at all three time points. Changes in LA strain and strain rate (sr) parameters were evaluated using repeated‐measures mixed‐effects models. The cohort was stratified according to development of cancer therapeutics‐related cardiac dysfunction (CTRCD) during follow‐up. Results The mean age was 52.7 ± 13.8 years, 25.3% had hypertension and 16.0% had metastatic disease. Multiple LA strain parameters (predicted delta value, [95%CI]) showed statistically significant declines in patients who developed CTRCD from baseline to the 3‐month follow‐up after multivariable adjustment; LA reservoir strain (LAεres): −4.7%; [−8.1% to −1.3%], p = .007; LA conduit strain (LAεcon): −2.8%; [−5.3% to −.4%], p = .021); and LAεres sr: −.2/s; [−.3/s to −.09/s], p < .001). In patients who did not develop CTRCD, LA strain parameters declined significantly but to a smaller degree than in the CTRCD group (LAεres: −1.7%; [−3.1% to −.3%], p = .020, LAεcon: −2.2%; [−3.3% to −1.1%], p < .001, and LA booster pump strain : −2.4%; [−3.5% to −1.4%], p < .001). LA strain rates did not decline significantly in the non‐CTRCD group. Conclusion Trastuzumab treatment was associated with declines in LA strain parameters in patients with breast cancer. The largest declines were observed in patients who developed CTRCD during treatment.
No takes yet. Share an insight, caveat, or question.
Lassen et al. (2024) conducted a cohort in stage I-IV HER2+ breast cancer (n=170). Trastuzumab vs. Baseline was evaluated on Change in LA reservoir strain from baseline to 3-month follow-up in patients who developed CTRCD (predicted delta value -4.7%, 95% CI -8.1% to -1.3%, p=0.007). Trastuzumab treatment was associated with declines in left atrial reservoir strain at 3 months, especially in those developing cardiac dysfunction (delta -4.7%; 95% CI -8.1% to -1.3%; p=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: